Goto K, Sugiyama K, Li R, Miyake Y, Ando T, Mizutani F, Terabe K, Mizuno K, Wada Y
Department of Pediatrics, Nagoya City University Medical School, Nagoya, Japan.
Pediatr Res. 1999 Jan;45(1):128-32. doi: 10.1203/00006450-199901000-00021.
To clarify the prevalence of Japanese children thought to be at a risk for infection with GB virus-C (GBV-C)/hepatitis G virus (HGV), we investigated the detection rates of serum GBV-C/ HGV ribonucleic acid (RNA) by reverse transcription-seminested PCR and serum anti-HGV-E2 antibody by ELISA in 162 children with histories of blood or plasma product transfusions or with liver diseases and performed phylogenetic analysis of the 5' noncoding region sequences of GBV-C/HGV genomes. Children with histories of transfusions were divided into those who had been treated with antineoplastic agents for malignant diseases (malignant group) and those who had received transfusions for nonmalignant diseases (nonmalignant group). Children with liver diseases were divided into hepatitis B (HBV), hepatitis C (HCV), and non-A-C hepatitis groups. We detected GBV-C/ HGV RNA in 11 of 33 (33.3%) and anti-HGV-E2 in 1 of 27 (3.7%) children in the malignant group and in 3 of 56 (5.4%) and 1 of 53 (1.9%) children, respectively, in the nonmalignant group. Neither GBV-C/HGV RNA nor anti-HGV-E2 was detected in the HBV and non-A-C hepatitis groups. GBV-C/HGV RNA and anti-HGV-E2 were detected in 7 of 23 (30.4%) and in 1 of 18 (5.6%) children, respectively, in the HCV group. All children positive for either GBV-C/HGV RNA or anti-HGV-E2, except one whose route of GBV-C/HGV infection suggested mother-to-infant transmission, had histories of transfusions. The phylogenetic analysis showed that all isolates in this study were divisible into three groups and that most of them were clustered into group 3 (Asian group).
为明确被认为有感染GB病毒C型(GBV-C)/庚型肝炎病毒(HGV)风险的日本儿童的感染率,我们采用逆转录半巢式聚合酶链反应(PCR)检测了162例有输血或血浆制品输注史或患有肝脏疾病儿童的血清GBV-C/HGV核糖核酸(RNA),并用酶联免疫吸附测定(ELISA)检测了血清抗HGV-E2抗体,同时对GBV-C/HGV基因组的5'非编码区序列进行了系统发育分析。有输血史的儿童被分为因恶性疾病接受抗肿瘤药物治疗的儿童(恶性组)和因非恶性疾病接受输血的儿童(非恶性组)。患有肝脏疾病的儿童被分为乙型肝炎(HBV)、丙型肝炎(HCV)和非甲非丙型肝炎组。在恶性组的33例儿童中,11例(33.3%)检测到GBV-C/HGV RNA,27例中的1例(3.7%)检测到抗HGV-E2;在非恶性组的56例儿童中,分别有3例(5.4%)和53例中的1例(1.9%)检测到GBV-C/HGV RNA和抗HGV-E2。在HBV组和非甲非丙型肝炎组中均未检测到GBV-C/HGV RNA和抗HGV-E2。在HCV组的23例儿童中,7例(30.4%)检测到GBV-C/HGV RNA,18例中的1例(5.6%)检测到抗HGV-E2。除1例GBV-C/HGV感染途径提示为母婴传播的儿童外,所有GBV-C/HGV RNA或抗HGV-E2阳性的儿童均有输血史。系统发育分析表明,本研究中的所有分离株可分为三组,其中大多数聚集在第3组(亚洲组)。